GREAT POINT PARTNERS LLC
Filing Date
Global Rank
#2,831
/ 8,622
▲ 743
· as of Mar 2026
Top Industry
Biotechnology
92.4%
3Y Alpha vs SPY
+9.8%
Period ended 4 months ago
Filed May 15, 2026 · 2mo
25 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+120.2%
SPY
+67.9%
Annualised alpha
+11.3%
Max drawdown
−61.9%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 98% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
42 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
7.2%
−2.5 pts
Top 5
31.1%
−6.4 pts
Top 10
52.5%
−10.8 pts
HHI
383
Diversified−130
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $435,120,103 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
8 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ZURA | Zura Bio Ltd | +400,000 | 4,215,930 | $25,084,783 | |
| VOR | Vor Biopharma Inc. | +379,893 | 1,750,000 | $31,220,000 | |
| CLYM | Climb Bio, Inc. | +354,596 | 1,334,130 | $9,138,790 | |
| SLN | Silence Therapeutics plc | +212,457 | 1,020,489 | $5,377,977 | |
| JBIO | Jade Biosciences, Inc. | +158,189 | 964,462 | $13,550,691 | |
| NGNE | Neurogene Inc. | +150,000 | 500,000 | $10,080,000 | |
| NKTR | Nektar Therapeutics | +105,721 | 316,453 | $22,768,793 | |
| CTNM | Contineum Therapeutics, Inc. | +198 | 800,198 | $10,450,585 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
4 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | −2,445,215 | 2,238,496 | $5,864,859 | |
| CGEM | Cullinan Therapeutics, Inc. | −334,032 | 300,000 | $4,263,000 | |
| IMVT | Immunovant, Inc. | −204,375 | 545,625 | $13,553,325 | |
| KALV | KalVista Pharmaceuticals, Inc. | −10,632 | 675,000 | $13,587,750 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
21 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | 3,000,800 | $23,016,136 | |
| SLGL | Sol-Gel Technologies Ltd. | 274,363 | $21,735,036 | |
| ALMS | Alumis Inc. | 856,061 | $18,859,023 | |
| DRUG | Bright Minds Biosciences Inc. | 220,000 | $16,053,400 | |
| ANNX | Annexon, Inc. | 2,500,000 | $13,850,000 | |
| ZBIO | Zenas BioPharma, Inc. | 524,066 | $10,245,490 | |
| MLTX | MoonLake Immunotherapeutics | 500,000 | $9,320,000 | |
| VERA | Vera Therapeutics, Inc. | 199,348 | $8,019,770 | |
| LBRX | Lb Pharmaceuticals Inc | 300,000 | $7,398,000 | |
| CMPX | Compass Therapeutics, Inc. | 1,350,000 | $7,141,500 | |
| SCYX | Scynexis Inc | 7,554,347 | $6,927,336 | |
| PALI | Palisade Bio, Inc. | 3,405,757 | $5,960,074 | |
| RLMD | Relmada Therapeutics, Inc. | 842,106 | $5,861,057 | |
| TENX | Tenax Therapeutics, Inc. | 327,307 | $5,233,638 | |
| PMN | ProMIS Neurosciences Inc. | 371,402 | $4,716,805 | |
| IMMX | Immix Biopharma, Inc. | 350,000 | $3,188,500 | |
| HUMA | Humacyte, Inc. | 3,750,000 | $2,276,250 | |
| GALT | Galectin Therapeutics Inc | 800,000 | $2,232,000 | |
| ALKS | Alkermes plc. | 50,000 | $1,768,000 | |
| AVXL | Anavex Life Sciences Corp. | 521,300 | $1,600,391 | |
| IRD | Opus Genetics, Inc. | 324,340 | $1,475,747 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
7 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | 250,000 | $19,852,500 | |
| SLNO | Soleno Therapeutics Inc | 400,000 | $18,520,000 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 350,000 | $14,423,500 | |
| FULC | Fulcrum Therapeutics, Inc. | 800,000 | $9,048,000 | |
| UPB | Upstream Bio, Inc. | 300,000 | $8,145,000 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 300,000 | $6,900,000 | |
| SANA | Sana Biotechnology, Inc. | 700,000 | $2,849,000 | |
| No positions match the current search. | ||||
42 tracked positions ·
$435,120,103 total
· filing declares
42 positions · $435,118,234
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
Held | 374,000 | $31,479,580 | 7.23% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Added | 1,750,000 | $31,220,000 | 7.18% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Added | 4,215,930 | $25,084,783 | 5.77% | |
| AMLX |
Amylyx Pharmaceuticals, Inc.
Healthcare
|
Held | 1,750,000 | $24,325,000 | 5.59% | |
| IBRX |
ImmunityBio, Inc.
PUT
Healthcare
|
NEW | 3,000,800 | $23,016,136 | 5.29% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Added | 316,453 | $22,768,793 | 5.23% | |
| SLGL |
Sol-Gel Technologies Ltd.
Healthcare
|
NEW | 274,363 | $21,735,036 | 5.00% | |
| ALMS |
Alumis Inc.
Healthcare
|
NEW | 856,061 | $18,859,023 | 4.33% | |
| DRUG |
Bright Minds Biosciences Inc.
Healthcare
|
NEW | 220,000 | $16,053,400 | 3.69% | |
| ANNX |
Annexon, Inc.
Healthcare
|
NEW | 2,500,000 | $13,850,000 | 3.18% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Reduced | 675,000 | $13,587,750 | 3.12% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 545,625 | $13,553,325 | 3.11% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 964,462 | $13,550,691 | 3.11% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
Added | 800,198 | $10,450,585 | 2.40% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
NEW | 524,066 | $10,245,490 | 2.35% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Added | 500,000 | $10,080,000 | 2.32% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
NEW | 500,000 | $9,320,000 | 2.14% | |
| CLYM |
Climb Bio, Inc.
Healthcare
|
Added | 1,334,130 | $9,138,790 | 2.10% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 183,330 | $8,992,336 | 2.07% | |
| EPRX |
Eupraxia Pharmaceuticals Inc.
Healthcare
|
Held | 1,200,000 | $8,688,000 | 2.00% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
NEW | 199,348 | $8,019,770 | 1.84% | |
| EVMN |
Evommune, Inc.
Healthcare
|
Held | 325,000 | $7,471,750 | 1.72% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
NEW | 300,000 | $7,398,000 | 1.70% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
NEW | 1,350,000 | $7,141,500 | 1.64% | |
| SCYX |
Scynexis Inc
Healthcare
|
NEW | 7,554,347 | $6,927,336 | 1.59% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
NEW | 3,405,757 | $5,960,074 | 1.37% | |
| CNTX |
Context Therapeutics Inc.
Healthcare
|
Reduced | 2,238,496 | $5,864,859 | 1.35% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
NEW | 842,106 | $5,861,057 | 1.35% | |
| SLN |
Silence Therapeutics plc
Healthcare
|
Added | 1,020,489 | $5,377,977 | 1.24% | |
| UNCY |
Unicycive Therapeutics, Inc.
Healthcare
|
Held | 796,558 | $5,241,351 | 1.20% | |
| TENX |
Tenax Therapeutics, Inc.
Healthcare
|
NEW | 327,307 | $5,233,638 | 1.20% | |
| PMN |
ProMIS Neurosciences Inc.
Healthcare
|
NEW | 371,402 | $4,716,805 | 1.08% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Reduced | 300,000 | $4,263,000 | 0.98% | |
| IMMX |
Immix Biopharma, Inc.
Healthcare
|
NEW | 350,000 | $3,188,500 | 0.73% | |
| RZLT |
Rezolute, Inc.
Healthcare
|
Held | 951,809 | $2,903,017 | 0.67% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Held | 82,800 | $2,339,100 | 0.54% | |
| HUMA |
Humacyte, Inc.
Healthcare
|
NEW | 3,750,000 | $2,276,250 | 0.52% | |
| GALT |
Galectin Therapeutics Inc
CALL
Healthcare
|
NEW | 800,000 | $2,232,000 | 0.51% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Held | 124,666 | $1,861,263 | 0.43% | |
| ALKS |
Alkermes plc.
Healthcare
|
NEW | 50,000 | $1,768,000 | 0.41% | |
| AVXL |
Anavex Life Sciences Corp.
CALL
Healthcare
|
NEW | 521,300 | $1,600,391 | 0.37% | |
| IRD |
Opus Genetics, Inc.
Healthcare
|
NEW | 324,340 | $1,475,747 | 0.34% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.